Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,313
Change Today -60.00 / -1.78%
Volume 13.5K
EVGN On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
As of 10:24 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

evogene ltd (EVGN) Snapshot

Open
$3,395
Previous Close
$3,373
Day High
$3,395
Day Low
$3,231
52 Week High
09/18/14 - $5,180
52 Week Low
08/24/15 - $3,015
Market Cap
841.3M
Average Volume 10 Days
24.1K
EPS TTM
$-0.69
Shares Outstanding
25.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOGENE LTD (EVGN)

Related News

No related news articles were found.

evogene ltd (EVGN) Related Businessweek News

No Related Businessweek News Found

evogene ltd (EVGN) Details

Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company operates in two segments, Evogene and Evofuel. The Evogene segment develops technologies to enhance plant performance through seed traits and ag-chemicals. Its seed trait operation utilizes to address yield and abiotic stress and biotic stress traits through the genetic modification or breeding of seeds; and ag-chemical operations utilize to develop novel crop protection and crop enhancement products, including herbicides. The Evofuel segment develops species of the castor bean plant for second generation feedstock for use in the alternative fuel industry, primarily biodiesel and biojet. Its products focus on various crops comprising corn, soybean, wheat, rice, and cotton. Evogene Ltd. has strategic collaborations with agricultural companies primarily to develop traits for yield and abiotic stress tolerance, such as enhanced tolerance to drought, heat, and salinity; and biotic stress resistance, including resistance to disease, pests, and insects. The company was founded in 1999 and is headquartered in Rehovot, Israel.

207 Employees
Last Reported Date: 04/30/15
Founded in 1999

evogene ltd (EVGN) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $436.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $245.0K
Executive Vice President of Technology Infras...
Total Annual Compensation: $252.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $244.0K
Executive Vice President of Strategy and Busi...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2014.

evogene ltd (EVGN) Key Developments

Evogene Ltd. to Establish Transformational and Validation Capabilities for Biotechnology Soybean

Evogene Ltd. announced that it intends to establish transformational and validation capabilities for biotechnology soybean. Activities will initially focus on soybean cyst nematode resistance with certain knowhow to be obtained from Syngenta pursuant to a recently signed amendment to the collaboration agreement targeting soybean cyst nematodes initially signed by the two companies in 2009, and extended in 2013. Under the amendment, validation activities for the candidate genes, which have already been discovered by Evogene under the nematode collaboration, will now be undertaken by Evogene, at its expense and under Syngenta's guidance, with enhanced commercial terms for Evogene. Moving into the area of gene transformation and validation in soybean represents an important capability for Evogene, in addition to its existing discovery capabilities, with respect to both its internal research efforts and future collaboration arrangements.

Evogene Ltd. Presents at Jefferies 11th Annual Industrials Conference, Aug-10-2015

Evogene Ltd. Presents at Jefferies 11th Annual Industrials Conference, Aug-10-2015 . Venue: Grand Hyatt, 109 E. 42nd Street, New York, New York, United States. Speakers: Ofer Haviv, Chief Executive Officer and President.

Evogene Ltd. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Evogene Ltd. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $2,656,000 compared with $3,850,000 for the same period a year ago. Operating loss was $4,642,000 compared with $3,728,000 for the same period a year ago. Net loss was $4,950,000 or $0.20 per basic and diluted share compared with $3,191,000 or $0.13 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $2,799,000 compared with $2,048,000 for the same period a year ago. Purchase of property, plant and equipment was $296,000 compared with $622,000 for the same period a year ago. For the six months, the company reported total revenues of $5,357,000 compared with $7,707,000 for the same period a year ago. Operating loss was $8,770,000 compared with $6,353,000 for the same period a year ago. Net loss was $8,359,000 or $0.33 per basic and diluted share compared with $5,528,000 or $0.22 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $5,371,000 compared with $5,271,000 for the same period a year ago. Purchase of property, plant and equipment was $849,000 compared with $925,000 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVGN:IT 3,313.00 -60.00

EVGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVGN.
View Industry Companies
 

Industry Analysis

EVGN

Industry Average

Valuation EVGN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOGENE LTD, please visit www.evogene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.